Ondansetron Accord Healthcare

Ondansetron, the active ingredient in Ondansetron Accord Healthcare, is a 5‑HT3 receptor antagonist presented as an injectable solution for intramuscular and intravenous use. It prevents nausea and vomiting associated with chemotherapy, postoperative recovery, and radiotherapy in adult patients.

GNH USA supplies Ondansetron Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide, ensuring quality and regulatory compliance across global markets, and our distribution network provides reliable logistics and timely delivery to meet the critical needs of healthcare providers.

Ondansetron acts on the serotonergic pathway to control nausea and vomiting in several clinical settings.

- Chemotherapy-induced nausea and vomiting: prevents and controls nausea and vomiting associated with cytotoxic chemotherapy. - Postoperative nausea and vomiting: reduces incidence of nausea and vomiting after surgical procedures. - Radiotherapy-induced nausea and vomiting: alleviates nausea and vomiting caused by radiotherapy treatments.

Ondansetron may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache - Constipation - Dizziness - Fatigue - Injection site pain or erythema - Diarrhea - Nausea - Dry mouth - Abdominal pain

Serious or Rare Side Effects: - QT interval prolongation and cardiac arrhythmias - Severe allergic reactions including anaphylaxis - Serotonin syndrome, especially with serotonergic drugs - Hypotension or cardiovascular collapse - Seizures

When using Ondansetron, several precautionary measures should be observed.

- Assess cardiac history: evaluate baseline QT interval before initiating therapy. - Monitor electrolytes: correct hypokalemia, hypomagnesemia, and hypocalcemia. - Use with caution in hepatic impairment: dose adjustment may be required. - Avoid concomitant use with other QT‑prolonging drugs: increased risk of arrhythmia. - Store at room temperature: keep in original container, protect from light and moisture.

Ondansetron can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Other 5‑HT3 antagonists: additive antiemetic effect may increase toxicity. - Drugs that prolong QT interval (e.g., quinidine, haloperidol): heightened risk of cardiac arrhythmias. - Apomorphine: may cause severe hypotension and loss of consciousness.

Moderate Interactions (Monitor Closely): - Cisplatin and other chemotherapeutics: may enhance emetogenic potential, requiring dose adjustment. - Rifampin: may reduce ondansetron plasma concentrations, decreasing efficacy. - Aprepitant: may increase ondansetron levels, raising risk of side effects.